Glial activation positron emission tomography imaging in radiation treatment of breast cancer brain metastases

Brain metastases affect more breast cancer patients than ever before due to increased overall patient survival with improved molecularly targeted treatments. Approximately 25–34% of breast cancer patients develop brain metastases in their lifetime. Due to the blood–brain barrier (BBB), the standard treatment for breast cancer brain metastases (BCBM) is surgery, stereotactic radiosurgery (SRS) and/or whole brain radiation therapy (WBRT). At the cost of cognitive side effects, WBRT has proven efficacy in treating brain metastases when used with local therapies such as SRS and surgery. This review investigated the potential use of glial activation positron emission tomography (PET) imaging for radiation treatment of BCBM. In order to put these studies into context, we provided background on current radiation treatment approaches for BCBM, our current understanding of the brain microenvironment, its interaction with the peripheral immune system, and alterations in the brain microenvironment by BCBM and radiation. We summarized preclinical literature on the interactions between glial activation and cognition and clinical studies using translocator protein (TSPO) PET to image glial activation in the context of neurological diseases. TSPO-PET is not employed clinically in assessing and guiding cancer therapies. However, it has gained traction in preclinical studies where glial activation was investigated from primary brain cancer, metastases and radiation treatments. Novel glial activation PET imaging and its applications in preclinical studies using breast cancer models and glial immunohistochemistry are highlighted. Lastly, we discuss the potential clinical application of glial activation imaging to improve the therapeutic ratio of radiation treatments for BCBM.

An anthropomorphic maxillofacial phantom using 3-dimensional printing, polyurethane rubber and epoxy resin for dental imaging and dosimetry

OBJECTIVE

The aim of this study was to construct an anthropomorphic maxillofacial phantom for dental imaging and dosimetry purposes using three-dimensional (3D) printing technology and materials that simulate the radiographic properties of tissues.

METHODS

Stereolithography photoreactive resins, polyurethane rubber and epoxy resin were modified by adding calcium carbonate and strontium carbonate powders or glass bubbles. These additives were used to change the materials' CT numbers to mimic various body tissues. A maxillofacial phantom was designed using CT images of a head.

RESULTS

Commercial 3D printing resins were found to have CT numbers near 120 HU and were used to print intervertebral discs and an external skin for the maxillofacial phantom. By adding various amounts of calcium carbonate and strontium carbonate powders the CT number of the resin was raised to 1000 & 1500 HU and used to print bone mimics. Epoxy resin modified by adding glass bubbles was used in assembly and as a cartilaginous mimic. Glass bubbles were added to polyurethane rubber to reduce the CT number to simulate soft tissue and filled spaces between the printed anatomy and external skin of the phantom.

CONCLUSION

The maxillofacial phantom designed for dental imaging and dosimetry constructed using 3D printing, polyurethane rubbers and epoxy resins represented a patient anatomically and radiographically. The results of the designed phantom, materials and assembly process can be applied to generate different phantoms that better represent diverse patient types and accommodate different ion chambers.